* 3-Dimensional Pharmaceuticals Inc., of Exton, Pa., appointedFrank Spiegel to the board of directors.

* GeneMedicine Inc., of The Woodlands, Texas, said GeorgeThornton, vice president for research and development, will leave thecompany on Jan. 31, 1996.

* Genzyme Corp., of Cambridge, Mass., named Peter Wirth as seniorvice president and general counsel

* Gilead Sciences Inc., of Foster City, Calif., said that James Denny,Gordon Moore and George Schultz have been named to the board ofdirectors.

* IntraBiotics Pharmaceuticals Inc., of Sunnyvale, Calif., appointedDavid Loury as director of preclinical development.

* Oncor Inc. and its subsidiary OncorPharm Inc., of Gaithersburg,Md., appointed Kenneth Culver as director of gene therapy researchand clinical affairs for OncorPharm. Culver helped pioneer the firsthuman use of gene therapy for treatment of inherited immunedeficiency.

* SangStat Medical Corp., of Menlo Park, Calif., said Maree Walljoined the company in the new position of vice president, investorrelations and business development.

(c) 1997 American Health Consultants. All rights reserved.